Diabetic Retinopathy Market to Reach USD 17.82 Billion by 2034 as Diabetes Cases and Aging Population Rise

The global diabetic retinopathy market is estimated at USD 10.13 billion in 2025 and is projected to climb to nearly USD 17.82 billion by 2034, advancing at a CAGR of 6.47% during the forecast period.

Ottawa, Sept. 17, 2025 (GLOBE NEWSWIRE) -- According to a study released by Towards Healthcare, a sister firm of Precedence Research, the diabetic retinopathy market was valued at USD 9.52 billion in 2024 and is anticipated to witness steady growth, reaching approximately USD 17.82 billion by 2034.

The global market is driven by the growing cases of diabetes and its complications, especially blindness, and the geriatric population.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5454

Key Takeaways

North America held a major share of the market in 2024.
Asia-Pacific is expected to grow at a notable CAGR in the studied years.
By type, the non-proliferative diabetic retinopathy segment led the diabetic retinopathy market in 2024.
By type, the proliferative diabetic retinopathy segment is expected to grow significantly during 2025-2034.
By management, the anti-VEGF segment was dominant in the market in 2024.
By management, the intraocular steroidal injection segment is expected to grow notably in the coming years.

Market Overview & Potential

High blood sugar leads to damage to the retina’s blood vessels, resulting in vision loss or blindness is termed diabetic retinopathy (DR). The global diabetic retinopathy market is stepping into novel developments, including a wider emphasis on early detection by employing Artificial Intelligence and optimized imaging, like Optical Coherence Tomography (OCT). Alongside ongoing approaches, like finding drug molecules targeting various pathways, more efficient and less often anti-VEGF agents, and potential therapies, especially gene therapy and dietary therapeutics.

What are the Key Drivers Involved in the Market Growth?

Globally expanding diabetic prevalence is mainly propelling the arrival of diabetic retinopathy. Alongside the worldwide rising awareness regarding the issue’s seriousness, leading to demand for screening and treatment, innovations in technology and new therapies are fueling the comprehensive diabetic retinopathy market expansion. Moreover, the global governments are boosting highly improved accenss to care and promoting healthcare infrastructure, which is assisting in the overall development of the market.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Ongoing Trends in the Diabetic Retinopathy Market?

A surge in AI innovations, diagnostic solutions for diabetic retinopathy is impacting the revolution in the respective market.

In August 2025, Ocular Therapeutix, Inc., received a Special Protocol Assessment (SPA) agreement from the U.S. Food and Drug Administration for its planned clinical trial of AXPAXLI in non-proliferative diabetic retinopathy (NPDR).
In June 2025, Avant Technologies, Inc., and its JV partner, Ainnova Tech, Inc., a major healthcare technology company, collaborated with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies, located in Central America.
In April 2025, Remidio Innovative Solutions, an AI-driven ophthalmic diagnostics firm, entered into a strategic partnership with RetinaRisk, a health tech company from Iceland, to accelerate risk-based diabetic retinopathy (DR) screening in India and Iceland.

What is the Significant Challenge in the Diabetic Retinopathy Market?

A rise in the need for specialized imaging equipment and advanced surgical procedures in diabetic retinopathy concerns is creating a barrier to the availability outside of specialized ophthalmology centers. This further restricts access for numerous people, especially in developing regions or rural areas. Sometimes, the escalating healthcare expenses for complex treatments like anti-VEGF injections and vitrectomy are also limiting the market growth.

Regional Analysis

Why did North America Dominate the Market in 2024?

In 2024, North America held a dominant share of the diabetic retinopathy market. Due to the growing diagnosis rate, showing a huge growth in the DR patients in the US and Canada, this is driving the market progress. Alongside the US’s robust government support and a favorable reimbursement landscape, comprising insurance coverage for treatments, resulting in diabetic eye care is cost-effective and accessible for patients. Recently, Roche's Susvimo received FDA approval for a sustained delivery of therapy every nine months, which lowers the need for often eye injections for some patients with DR.

For instance,

In July 2025, Samsung Bioepis partnered with Harrow for the commercialization of its ophthalmology biosimilars portfolio in the United States.

What Made the Asia Pacific Grow Significantly in the Market in 2024?

During the prospective period, the Asia Pacific is predicted to register rapid growth in the diabetic retinopathy market. China and India’s expanding aging population linked with diabetes is leading to DR, which further fuels a greater demand for advanced treatment solutions. Changing lifestyle and urbanization in ASAP’s countries are propelling a rise in these diabetic cases. In recent days, India’s activities have been focusing on rural populations by employing the Rapid Assessment of Avoidable Blindness (RAAB) survey to acquire data rapidly and inform intervention planning.

For this market,

In October 2024, Google made an AI partnership with India-based medical device startup Forus Health and AuroLab to scale screening for diabetic retinopathy.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By type analysis

How did the Non-Proliferative Diabetic Retinopathy Segment Lead the Market in 2024?

In 2024, the non-proliferative diabetic retinopathy segment captured a major share of the diabetic retinopathy market. This type of DR is less severe and preventable with non-invasive treatments, like lifestyle changes, stricter blood sugar control, and therapeutics to lower swelling. The emergence of Ultra-Widefield Angiography facilitates a complete view of the retina, supports the identification of non-perfused areas, and assists in risk stratification for NPDR. The use of early treatment with intravitreal anti-VEGF injections (like aflibercept) in moderate to severe NPDR is fueling the overall market development.

Whereas the proliferative diabetic retinopathy segment is predicted to expand notably in the coming era. The globe is facing a rise in an aging population, with vision impairment, which ultimately leads to PDR, and further drives demand for robust diagnostic and treatment solutions. Novel treatment approaches, such as internal limiting membrane (ILM) peeling, help in relieving traction on the retina, with retinotomy and retinectomy reserved for severe cases. Along with this, ongoing efforts are being made in the adoption of laser treatment integrated with anti-VEGF therapy for patients with high-risk features or a high risk of not adhering to follow-up care.

By management analysis

Why did the Anti-VEGF Segment Dominate the Market in 2024?

The anti-VEGF segment held the biggest revenue share of the diabetic retinopathy market in 2024. A huge pool of type 2 diabetes is a major cause of blindness in elderly people is propelling the further generation of diabetic retinopathy, which accelerates demand for anti-VEGF therapies. A prominent development in delivery methods, particularly implantable devices and gene therapy, is lowering injection frequency, and the progression of novel drugs like faricimab, which targets both VEGF and angiopoietin-2. Moreover, anti-VEGF therapy is employed alone or in combination with other treatments, such as panretinal photocoagulation (PRP) laser treatment, acts as a gold standard for some high-risk instances.

Although the intraocular steroidal injection segment is estimated to register a significant expansion during 2025-2034. This kind of management is increasingly used in the requirement for long-acting treatments for patients unresponsive to anti-VEGF therapy. Ongoing revolutionary approaches, including dexamethasone (Ozurdex) and fluocinolone acetonide (Iluvien), enable sustained drug release for months or even years, minimizing the need for repeated injections. Furthermore, steroids are employed in conjunction with other treatments, like anti-VEGF injections or laser therapy, which escalates treatment outcomes, mainly in patients with pseudophakia (eyes with prior cataract surgery).

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

What are the Ongoing Developments in the Diabetic Retinopathy Market?

In August 2025, REGENXBIO Inc. started a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
In June 2025, Outlook Therapeutics, Inc., a biopharmaceutical company, introduced LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD) in Germany and the UK.
In April 2025, Dr. Mohan’s Diabetes Centre unveiled an AI-powered tool for early diabetic retinopathy detection.

Diabetic Retinopathy Market Key Players List

ABBVIE INC.
Novartis AG
Oxurion NV
Sirnaomics
Alimera Sciences
Ampio Pharmaceuticals Inc.
BCNPeptides
Kowa Company Ltd.
Genentech, Inc.
Bayer AG
Roche

Browse More Insights of Towards Healthcare:

The global industrial microbiology market was valued at USD 12.75 billion in 2024, increased to USD 13.63 billion in 2025, and is projected to reach USD 24.92 billion by 2034, expanding at a CAGR of 6.93% from 2025 to 2034.

The U.S. healthcare CRM market stood at USD 9.92 million in 2024, rose to USD 10.64 million in 2025, and is anticipated to hit USD 19.94 million by 2034, growing at a CAGR of 7.23% between 2025 and 2034.

The global hospital outsourcing market was valued at USD 381.74 billion in 2024, grew to USD 421.21 billion in 2025, and is forecasted to reach USD 1021.17 billion by 2034, advancing at a CAGR of 10.34% during the forecast period.

The global women’s health app market was worth USD 4.89 billion in 2024, expanded to USD 5.76 billion in 2025, and is estimated to reach USD 25.18 billion by 2034, registering the fastest growth with a CAGR of 17.81% between 2025 and 2034.

The global stroke rehabilitation market accounted for USD 285 million in 2024, climbed to USD 317.02 million in 2025, and is expected to achieve USD 817.06 million by 2034, progressing at a CAGR of 11.24% from 2025 to 2034.

The Europe pharmaceutical CDMO market was valued at USD 35.48 billion in 2024, grew to USD 37.98 billion in 2025, and is likely to reach USD 70.05 billion by 2034, expanding at a CAGR of 7.04% throughout the forecast period.

The U.S. pharmaceutical CDMO market generated USD 36.77 billion in 2024, increased to USD 39.14 billion in 2025, and is projected to hit USD 68.57 billion by 2034, recording a CAGR of 6.43% between 2025 and 2034.

The global research grade proteins market was valued at USD 1.13 billion in 2024, rose to USD 1.31 billion in 2025, and is anticipated to reach USD 4.81 billion by 2034, advancing at a strong CAGR of 15.57% over the forecast years.

The global personalized retail nutrition and wellness market was worth USD 3.94 billion in 2024, increased to USD 4.54 billion in 2025, and is projected to reach USD 16.25 billion by 2034, expanding at a CAGR of 15.22% between 2025 and 2034.

The global cell cryopreservation market was calculated at USD 11.48 billion in 2024, grew to USD 13.89 billion in 2025, and is forecasted to soar to USD 77.52 billion by 2034, demonstrating the fastest expansion at a CAGR of 21.05% during the forecast period.

Segments Covered in The Report

By Type

Proliferative Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy

By Management

Anti-VEGF
Intraocular Steroid Injection
Laser Surgery
Vitrectomy

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5454

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.